

# Early-life gut microbiome composition and milk allergy resolution



Supinda Bunyavanich, MD, MPH,<sup>a,b</sup> Nan Shen, MS,<sup>a</sup> Alexander Grishin, PhD,<sup>b</sup> Robert Wood, MD,<sup>c</sup> Wesley Burks, MD,<sup>d</sup> Peter Dawson, PhD,<sup>e</sup> Stacie M. Jones, MD,<sup>f</sup> Donald Y. M. Leung, MD, PhD,<sup>g</sup> Hugh Sampson, MD,<sup>b</sup> Scott Sicherer, MD,<sup>b</sup> and Jose C. Clemente, PhD<sup>a,h</sup> *New York, NY, Baltimore and Rockville, Md, Chapel Hill, NC, Little Rock, Ark, and Denver, Colo*

**Background:** Gut microbiota may play a role in the natural history of cow's milk allergy.

**Objective:** We sought to examine the association between early-life gut microbiota and the resolution of cow's milk allergy.

**Methods:** We studied 226 children with milk allergy who were enrolled at infancy in the Consortium of Food Allergy observational study of food allergy. Fecal samples were collected at age 3 to 16 months, and the children were followed longitudinally with clinical evaluation, milk-specific IgE levels, and milk skin prick test performed at enrollment, 6 months, 12 months, and yearly thereafter up until age 8 years. Gut microbiome was profiled by 16s rRNA sequencing and microbiome analyses performed using Quantitative Insights into Microbial Ecology (QIIME), Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), and Statistical Analysis of Metagenomic Profiles (STAMP).

**Results:** Milk allergy resolved by age 8 years in 128 (56.6%) of the 226 children. Gut microbiome composition at age 3 to 6 months was associated with milk allergy resolution by age 8 years (PERMANOVA  $P = .047$ ), with enrichment of *Clostridia* and *Firmicutes* in the infant gut microbiome of subjects whose milk allergy resolved. Metagenome functional prediction

supported decreased fatty acid metabolism in the gut microbiome of subjects whose milk allergy resolved ( $\eta^2 = 0.43$ ; ANOVA  $P = .034$ ).

**Conclusions:** Early infancy is a window during which gut microbiota may shape food allergy outcomes in childhood. Bacterial taxa within *Clostridia* and *Firmicutes* could be studied as probiotic candidates for milk allergy therapy. (J Allergy Clin Immunol 2016;138:1122-30.)

**Key words:** Cow's milk allergy, microbiome, microbiota, Clostridia, Firmicutes, Bacteroidetes, metagenome, fatty acid, food allergy, 16s rRNA sequencing

Discuss this article on the JACI Journal Club blog: [www.jaci-online.blogspot.com](http://www.jaci-online.blogspot.com).

Cow's milk allergy is the most common food allergy in young children, affecting 2% to 3%.<sup>1,2</sup> Individuals with milk allergy are at risk for allergic reactions and also face challenges in finding suitable replacements for the nutritional content that milk-based products provide.<sup>3</sup> A child may have to live with the limitations imposed by milk allergy for several years, as recent studies have shown that milk allergy often continues into later childhood

From <sup>a</sup>the Department of Genetics and Genomic Sciences and Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York; <sup>b</sup>the Division of Pediatric Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York; <sup>c</sup>the Department of Pediatrics, Johns Hopkins University, Baltimore; <sup>d</sup>the Department of Pediatrics, University of North Carolina, Chapel Hill; <sup>e</sup>Emmes Corporation, Rockville; <sup>f</sup>the Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock; <sup>g</sup>the Department of Pediatrics, National Jewish Health, Denver; and <sup>h</sup>the Department of Medicine, Division of Clinical Immunology and Immunology Institute, Icahn School of Medicine at Mount Sinai, New York.

This study was supported by the National Institutes of Health (K08AI093538, R01AI118833, U19AI066738 and U01AI066560), SUCCESS, Crohn's and Colitis Foundation of America (CCFA #362048), and the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. The project was also supported by grant nos. UL1 TR-000154 (National Jewish), UL1 TR-000067 (Mount Sinai), UL1 TR-000039 (Arkansas), UL1 TR-000083 (U North Carolina) and UL1 TR-000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health.

Disclosure of potential conflict of interest: S. Bunyavanich has received a grant from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases. A. Grishin has received a grant from the NIH/National Institute of Allergy and Infectious Diseases and has consultant arrangements with Allertein Therapeutics, LLC. R. Wood has received a grant from the National Institutes of Health, DBV, and Aimmune; has consultant arrangements with Stallergenes and Sanofi; is employed by Johns Hopkins University; and receives royalties from UpToDate. W. Burks has received grants from the Food Allergy & Anaphylaxis Network, NIH, and Wallace Research Foundation; has received personal fees from FARE, NIH Allergy, Immunology and Transplantation Research Committee Review Panel, NIH Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section, World Allergy Organization, Adept Field Solutions, Aimmune Therapeutics, Inc, Epiva Biosciences, Inc, Genentech, GLG Research, Inc, Merck, SRA International, Stallergenes, Valeant Pharmaceuticals North America, LLC, PPD Development, LP, American Society for Microbiology, and Allertein; and has received nonfinancial

support from Dow AgroSciences, Insys Therapeutics, and Regeneron Pharmaceuticals, Inc. P. Dawson has received a grant from the NIH/National Institute of Allergy and Infectious Diseases/Division of Allergy, Immunology, and Transplantation. S. M. Jones is a member of the research advisory board for Food Allergy Research Education; has consultant arrangements with Stallergenes; has received grants from the NIH/National Institute of Allergy and Infectious Diseases, Food Allergy Research Education, Allergy Research Corporation, DBV Technologies, and the National Peanut Board; has received payment for lectures from the Kansas City Allergy Society, Mercy Children's Hospital, Riley Children's Hospital, Southwestern Medical School-Children's Medical Center, the European Academy of Allergy & Clinical Immunology, the New York Allergy & Asthma Society, the Iowa Society of Allergy, Asthma & Immunology, and the University of Iowa Paul M. Seeborn Lectureship in Allergy. D. Y. M. Leung has received a grant from the NIH/National Institute of Allergy and Infectious Diseases. H. Sampson has received a grant from the National Institute of Allergy and Infectious Diseases; has consultant arrangements with Allertein Therapeutics, LLC, Genentech, Sanofi, Stallergenes, and Merck; is a part-time employee of DBV Technologies as the Chief Scientific Officer; and has received stock options from Allertein Therapeutics and DBV Therapeutics. S. Sicherer has received a grant from the National Institute of Allergy and Infectious Diseases and has received royalties from UpToDate. J. C. Clemente has received grants from the SUCCESS fund (GCO14-0560) and Crohn's and Colitis Foundation of America (grant no. 362048). N. Shen declares no relevant conflicts of interest.

Received for publication November 30, 2015; revised February 24, 2016; accepted for publication March 22, 2016.

Available online May 10, 2016.

Corresponding author: Supinda Bunyavanich, MD, MPH, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, #1498, New York, NY 10029. E-mail: [supinda@post.harvard.edu](mailto:supinda@post.harvard.edu). Or: [jose.clemente@mssm.edu](mailto:jose.clemente@mssm.edu).

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749/\$36.00

© 2016 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaci.2016.03.041>

#### Abbreviations used

CoFAR: Consortium of Food Allergy Research  
LDA: Linear discriminant analysis  
LefSe: Linear discriminant analysis effect size  
OTU: Operational taxonomic unit  
PCoA: Principal coordinate analysis  
sIgE: Specific IgE  
SPT: Skin prick test

and adulthood.<sup>1,4</sup> Parents of milk-allergic children often ask allergists to gauge whether their child's milk allergy will resolve.

We hypothesized that gut microbiota play a role in the natural history of milk allergy, as the etiology of food allergy is thought to involve deviation from the default state of mucosal immune tolerance that may be driven by diet, commensal microbiota, and interactions between them.<sup>5,6</sup> Variations in infant gut flora have been associated with allergy skin prick test (SPT) response,<sup>7</sup> specific IgE (sIgE) levels,<sup>8</sup> atopic dermatitis,<sup>8,9</sup> and food allergy status.<sup>10</sup> Much of this previous work has relied on culture methods, which allow for examination of species specifically targeted and cultured, but exclude the large majority of bacterial organisms that cannot be cultured. These excluded organisms may play key roles in the natural history of milk allergy.

In this study, we used high-throughput sequencing to comprehensively characterize the gut microbiota of 226 children aged 3 to 16 months with cow's milk allergy. We followed these children up to age 8 years and examined for associations between early-life gut microbiota diversity, composition, and milk allergy resolution.

## METHODS

Study protocols were approved by the institutional review boards of the participating institutions.

### Study design and subjects

The subjects of this study are a subset of a larger observational cohort study by the Consortium of Food Allergy Research (CoFAR) of 512 participants with milk allergy, egg allergy, and/or moderate-to-severe atopic dermatitis but without known peanut allergy.<sup>1,11</sup> Participants were recruited at age 3 to 15 months from 5 study centers across the United States and were followed over time. The study sites included the Icahn School of Medicine at Mount Sinai, New York, New York; Duke University School of Medical Center, Durham, North Carolina; Johns Hopkins University School of Medicine, Baltimore, Maryland; National Jewish Health, Denver, Colorado; and Arkansas Children's Hospital, Little Rock, Arkansas. The goal of the CoFAR observational study was to identify factors associated with the development of peanut allergy in a high-risk cohort. Examination of the natural histories of milk and egg allergy was a secondary objective.

We collected stool from 234 of the 244 CoFAR observational study participants who had milk allergy at study entry. Stool samples were collected at or near the time of enrollment. Samples were collected during a study visit or by the parent at home using a stool collection kit provided by CoFAR. For this study, we excluded from the analysis 3 subjects who submitted stool samples after age 17 months, yielding 231 stool samples from 231 participants for DNA isolation.

### DNA isolation and sequencing

DNA was isolated using the MoBio Power Soil DNA Isolation kit (Carlsbad, Calif). The V4 region of the 16S *rRNA* gene was amplified with barcoded primers and 16S rRNA sequencing was performed on the Illumina MiSeq platform using 2 × 250 bp paired-end read. Stool samples from 5 participants yielded less than 2000 sequences/sample (2.2% of 231 samples

sequenced) and these subjects were removed from the analysis, yielding a final sample size of 226 subjects for analysis. In total, 5,478,379 sequences were assigned to 16S rRNA gene sequences for the 226 samples, with a median of 23,682 sequences per sample.

## Outcomes

Data were prospectively collected from study enrollment up through a visit at approximately age 8 years. Participants were considered to have milk allergy if they had either (1) positive physician-supervised oral food challenge or a convincing reaction and sensitization to milk by milk sIgE level of 0.35 kU<sub>A</sub>/L or more and/or SPT wheal of more than 3 mm, or (2) a flare of atopic dermatitis associated with milk ingestion along with a milk sIgE level of more than 5 kU<sub>A</sub>/L. At entry, dietary, medical, and social histories were obtained by questionnaires administered to the parents of participants. Milk sIgE levels measurement and milk SPT were carried out at entry and periodically thereafter as clinically indicated. Atopic dermatitis severity was graded on the basis of criteria previously described.<sup>1</sup> Participants were evaluated in person at enrollment, 6 months, 12 months, and yearly thereafter with additional telephone follow-up between each visit. Milk allergy was considered persistent if the subject had milk allergy according to the above definitions at the last documented encounter.

We used logistic regression implemented in R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria) to test for the associations between early-life exposures that shaped the infant gut microbiome (mode of delivery, breast-feeding, solid food intake, antibiotic use) and milk allergy resolution by age 8 years or milk allergen sensitization.

## Microbiome analyses

On the basis of observations from previous studies<sup>12,13</sup> of marked shifts in the gut microbiome composition in early life associated with developmental stages (eg, predominant nutrition from breastmilk and formula until age 6 months, predominant nutrition from solid food and transition to whole milk or milk alternatives around 12 months), we *a priori* stratified the participants into the following 3 groups for microbiome analysis: participants whose stool samples were obtained at (1) age 3 to 6 months, (2) age 7 to 12 months, and (3) age 13 to 16 months. The members of the investigative team who conducted the microbiome and bioinformatic analyses had no role in acquiring or assessing the clinical results of the cohort study.

Unless noted otherwise, we performed all analyses using Quantitative Insights into Microbial Ecology (QIIME) 1.8.0, an open-source bioinformatics pipeline for performing analysis of microbiome sequence data. Operational taxonomic units (OTUs), defined as taxonomic units based on DNA sequences that share high identity,<sup>14</sup> were constructed using a more than 97% similarity threshold. Within the 3 age groups for analysis, alpha diversity (the richness of a sample in terms of the diversity of OTUs observed in it) was estimated using Faith's phylogenetic diversity.<sup>15</sup> Beta diversity (distance between samples based on differences in OTUs present in each sample) was measured using unweighted UniFrac.<sup>16</sup> Principal coordinate analysis (PCoA) was used to visualize clustering patterns between samples based on beta diversity distances. Linear discriminant analysis effect size (LEfSe),<sup>17</sup> a method for biomarker discovery, was used to determine taxa that best characterize each population, ie, bacterial groups associated with milk allergy resolution or persistence. LEfSe scores measure the consistency of differences in relative abundance between taxa in the groups analyzed (ie, resolution vs persistence), with a higher score indicating higher consistency. Association between microbiome composition and covariates was tested using PERMANOVA, a nonparametric test similar to ANOVA but that does not require the data to be normally distributed. Significance of PERMANOVA tests was determined using 999 permutations with adjustment for multiple testing.

## Prediction of metagenome functional content

We used Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) 1.0.0<sup>18</sup> to predict metagenome function from the 16S *rRNA* data. Bray-Curtis distances were used to determine similarity

Download English Version:

<https://daneshyari.com/en/article/5646668>

Download Persian Version:

<https://daneshyari.com/article/5646668>

[Daneshyari.com](https://daneshyari.com)